The University of California, Davis (UC Davis) has been awarded a $811,009 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research program) to develop a microfluidic device that can capture and separate peripheral B cells based on their B cell receptor (BCR) binding avidity to a defined antigen. The goal is to characterize the relationship between BCR binding avidity dynamics and immune status following influenza virus infection. This technology, called the Shear-Force Avidity-based Cell Selector (SACS), aims to provide a rapid and adaptable system to evaluate functional B cell responses to influenza and other pathogens like SARS-CoV-2. The five-year project period runs from November 13, 2024 to October 31, 2029.
Generated 2/25/25, 3:18 AM